CD4 Cell Count: A Critical Tool in the Human Immunodeficiency Virus Response

1360 • cid 2022:74 (15 April) • EDITORIAL COMMENTARY Received 15 July 2021; editorial decision 21 July 2021; published online 26 July 2021. Correspondence: N. Ford, Human Immunodeficiency Virus, Hepatitis, and Sexually Transmitted Infections Unit, World Health Organization, 1211 Geneva 27, Switzerland (fordn@ who.int). Clinical Infectious Diseases 2022;74(8):1360–1 © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http:// creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. https://doi.org/10.1093/cid/ciab658 CD4 Cell Count: A Critical Tool in the Human Immunodeficiency Virus Response

[1]  S. Lockman,et al.  Advanced HIV disease in the botswana combination prevention project: prevalence, risk factors, and outcomes. , 2020, AIDS.

[2]  C. Denkinger,et al.  Diagnostic accuracy of a novel tuberculosis point-of-care urine lipoarabinomannan assay for people living with HIV: A meta-analysis of individual in- and outpatient data , 2020, PLoS medicine.

[3]  N. Ford,et al.  Trends in CD4 and viral load testing 2005 to 2018: Multi-cohort study of people living with HIV in Southern Africa , 2020 .

[4]  J. Etard,et al.  Distribution of advanced HIV disease from three high HIV prevalence settings in Sub-Saharan Africa: a secondary analysis data from three population-based cross-sectional surveys in Eshowe (South Africa), Ndhiwa (Kenya) and Chiradzulu (Malawi) , 2019, Global health action.

[5]  T. Le.  World Health Organization Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy , 2018 .

[6]  N. Ford,et al.  CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  N. Ford,et al.  The Continuing Burden of Advanced HIV Disease Over 10 Years of Increasing Antiretroviral Therapy Coverage in South Africa , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  N. Ford,et al.  Persistent High Burden of Advanced HIV Disease Among Patients Seeking Care in South Africa’s National HIV Program: Data From a Nationwide Laboratory Cohort , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Richard D Moore,et al.  Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  N. Ford,et al.  The WHO public health approach to HIV treatment and care: looking back and looking ahead. , 2017, The Lancet. Infectious diseases.

[11]  A. Boulle,et al.  Contemporary disengagement from antiretroviral therapy in Khayelitsha, South Africa: A cohort study , 2017, PLoS medicine.

[12]  K. Maitland,et al.  Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa , 2017, The New England journal of medicine.

[13]  S. Eholie,et al.  Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual question , 2016, AIDS Research and Therapy.

[14]  N. Ford,et al.  Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. , 2015, The lancet. HIV.

[15]  Evangelos Kontopantelis,et al.  Regression based quasi-experimental approach when randomisation is not an option: interrupted time series analysis , 2015, BMJ : British Medical Journal.

[16]  L. Guinness,et al.  Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial , 2015, The Lancet.

[17]  O. Sued,et al.  Co-trimoxazole prophylaxis in adults, including pregnant women, with HIV: a systematic review and meta-analysis. , 2015, The lancet. HIV.

[18]  C. Gilks,et al.  A Single CD4 Test with 250 Cells/Mm3 Threshold Predicts Viral Suppression in HIV-Infected Adults Failing First-Line Therapy by Clinical Criteria , 2013, PloS one.

[19]  N. Ford,et al.  HIV viral load monitoring in resource-limited regions: optional or necessary? , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  S. Gove,et al.  The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings , 2006, The Lancet.

[21]  Alexander C. Wagenaar,et al.  The Value of Interrupted Time-Series Experiments for Community Intervention Research , 2000, Prevention Science.

[22]  Donald T. Campbell,et al.  Reforms as Experiments , 1969 .